BiotechAnalyzer

Positive signal: Enrollment surpassed target ahead of time; maintain current recruitment pace.

Urgent: Review the updated FDA label guidance before tomorrow's submission.

Phase III topline data expected next week. Analysts call scheduled for March 12th.

Positive signal: Enrollment surpassed target ahead of time; maintain current recruitment pace.

Urgent: Review the updated FDA label guidance before tomorrow's submission.